{
    "clinical_study": {
        "@rank": "148178", 
        "acronym": "MOA 034", 
        "arm_group": {
            "arm_group_label": "HP802-247", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Assess the influence of HP802-247 on biochemical and cellular markers of inflammation in\n      chronic venous leg ulcers"
        }, 
        "brief_title": "A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Venous Leg Ulcers", 
        "condition_browse": {
            "mesh_term": [
                "Leg Ulcer", 
                "Ulcer", 
                "Varicose Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provide informed consent\n\n          -  Age \u2265 18 years and of either sex\n\n          -  Willing to comply with protocol instructions, including allowing all study\n             assessments\n\n          -  Have a venous leg ulcer (VLU) between the knee and ankle (at or above the malleolus),\n             with a surface area \u2265 4.0 cm x cm and \u2264 15.0 cm x cm\n\n          -  Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular\n             or venous incompetence\n\n          -  Arterial supply adequacy confirmed\n\n          -  Target ulcer involves a full thickness skin loss, but WITHOUT exposure of tendon,\n             muscle, or bone\n\n          -  Target ulcer duration \u2265 12 weeks but \u2264 104 weeks (24 months).\n\n          -  Acceptable state of health and nutrition\n\n        Exclusion Criteria:\n\n          -  History of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin,\n             bovine serum albumin or bovine serum proteins, penicillin, streptomycin, amphotericin\n             B or any other component of HP802-247,or known sensitivity to Iodine\n\n          -  Prior diagnosis of Systemic Lupus Erythematosus with elevated anti-DNA antibody\n             titers, Buerger's disease (thromboangiitis obliterans), current diagnosis of\n             vasculitis, or current diagnosis of claudication\n\n          -  Therapy with another investigational agent within thirty (30) days of Screening, or\n             during the study, or any participation in a previous HP802-247 trial\n\n          -  A target ulcer of non-venous etiologies (e.g., sickle cell anemia, necrobiosis\n             lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic)\n\n          -  Documented history of osteomyelitis at the target wound location within 6 months\n             preceding the Screening Visit\n\n          -  Refusal of or inability to tolerate compression therapy\n\n          -  Therapy of the target ulcer with Collagenase Santyl\u00ae ointment, autologous skin graft,\n             biological dressings or living cell products (e.g., Oasis\u00ae, Apligraf\u2122, Dermagraft\u2122)\n             within 30 days preceding the Screening Visit\n\n          -  Therapy of the target ulcer with topical growth factors within 1 week preceding the\n             Screening Visit\n\n          -  Current therapy with systemic antibiotics\n\n          -  Current systemic therapy with cytotoxic drugs\n\n          -  Current therapy with chronic (> 10 days) oral corticosteroids\n\n          -  Current therapy with TNF\u03b1 inhibitors\n\n          -  History of cancer in the preceding 5 years (other than carcinoma in situ of the\n             cervix or adequately treated non-melanoma skin cancers)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02154087", 
            "org_study_id": "802-247-09-034"
        }, 
        "intervention": {
            "arm_group_label": "HP802-247", 
            "description": "260 \u00b5L (130 \u00b5L, one spray, of each component) containing 0.5 x 10.6 cells per mL, alternating weekly with Vehicle", 
            "intervention_name": "HP802-247", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Venous leg ulcer", 
            "Ulcer", 
            "Venous stasis", 
            "Compression"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers", 
        "overall_contact": {
            "email": "jaime.dickerson@smith-nephew.com", 
            "last_name": "Jaime E Dickerson, PhD", 
            "phone": "817-302-3914"
        }, 
        "overall_contact_backup": {
            "email": "nick.mccoy@smith-nephew.com", 
            "last_name": "Nick McCoy", 
            "phone": "817-239-4801"
        }, 
        "overall_official": {
            "affiliation": "Smith & Nephew Biotherapeutics; Chief Medical Officer", 
            "last_name": "Herbert B Slade, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Determine change from baseline in cell numbers in subjects with VLU following the first dose of HP802-247", 
                "safety_issue": "No", 
                "time_frame": "5 weeks"
            }, 
            {
                "measure": "= Determine change from baseline in cell types in subjects with VLU following the first dose of HP802-247", 
                "safety_issue": "No", 
                "time_frame": "5 weeks"
            }, 
            {
                "measure": "= Determine change from baseline in biochemical markers of inflammation in subjects with VLU following the first dose of HP802-247", 
                "safety_issue": "No", 
                "time_frame": "5 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02154087"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Wound closure, defined as complete re-epithelization with no drainage or need for a dressing, will be recorded as a secondary outcome measure following up to 12 weeks of dosing", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "Smith & Nephew, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Smith & Nephew, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}